What Should Investors Know About Revolution Medicines (RVMD) Stock?

By Emilio Sanchez • Wednesday, November 08 12:13 • Permanent Link

More and more people are talking about Revolution Medicines over the last few weeks. Is it worth buying the Biotechnology stock at a price of $21.41? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Revolution Medicines has moved 13.0% over the last year, and the S&P 500 logged a change of 17.0%
RVMD has an average analyst rating of buy and is -40.53% away from its mean target price of $36.0 per share
Its trailing earnings per share (EPS) is $-3.26
Revolution Medicines has a trailing 12 month Price to Earnings (P/E) ratio of -6.6 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-3.47 and its forward P/E ratio is -6.2
The company has a Price to Book (P/B) ratio of 2.8 in contrast to the S&P 500's average ratio of 2.95
Revolution Medicines is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $-162790128, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.